Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2009 1
2010 1
2011 3
2012 1
2013 1
2014 1
2015 3
2016 1
2017 4
2018 1
2019 1
2020 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab.
Dominguez-Mozo MI, Perez-Perez S, Villar LM, Oliver-Martos B, Villarrubia N, Matesanz F, Costa-Frossard L, Pinto-Medel MJ, García-Sánchez MI, Ortega-Madueño I, Lopez-Lozano L, Garcia-Martinez A, Izquierdo G, Fernández Ó, Álvarez-Cermeño JC, Arroyo R, Alvarez-Lafuente R. Dominguez-Mozo MI, et al. Sci Rep. 2020 Aug 28;10(1):14244. doi: 10.1038/s41598-020-71283-5. Sci Rep. 2020. PMID: 32859922 Free PMC article.
Skin Phototype Could Be a Risk Factor for Multiple Sclerosis.
Urbaneja P, Hurtado-Guerrero I, Hernández MÁ, Oliver-Martos B, Oreja-Guevara C, Ortega-Pinazo J, Alonso A, Barón-López FJ, Leyva L, Fernández Ó, Pinto-Medel MJ. Urbaneja P, et al. J Clin Med. 2020 Jul 26;9(8):2384. doi: 10.3390/jcm9082384. J Clin Med. 2020. PMID: 32722577 Free PMC article.
Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation.
Hurtado-Guerrero I, Hernáez B, Pinto-Medel MJ, Calonge E, Rodriguez-Bada JL, Urbaneja P, Alonso A, Mena-Vázquez N, Aliaga P, Issazadeh-Navikas S, Pavia J, Leyva L, Alcamí J, Alcamí A, Fernández Ó, Oliver-Martos B. Hurtado-Guerrero I, et al. Among authors: pinto medel mj. J Clin Med. 2020 Mar 31;9(4):959. doi: 10.3390/jcm9040959. J Clin Med. 2020. PMID: 32244308 Free PMC article.
Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis.
Villarrubia N, Rodríguez-Martín E, Alari-Pahissa E, Aragón L, Castillo-Triviño T, Eixarch H, Ferrer JM, Martínez-Rodríguez JE, Massot M, Pinto-Medel MJ, Prada Á, Rodríguez-Acevedo B, Urbaneja P, Gascón-Gimenez F, Herrera G, Hernández-Clares R, Salgado MG, Oterino A, San Segundo D, Cuello JP, Gil-Herrera J, Cámara C, Gómez-Gutiérrez M, Martínez-Hernández E, Meca-Lallana V, Moga E, Muñoz-Calleja C, Querol L, Presas-Rodríguez S, Teniente-Serra A, Vlagea A, Muriel A, Roldán E, Villar LM. Villarrubia N, et al. Clin Chim Acta. 2019 Jan;488:135-142. doi: 10.1016/j.cca.2018.11.008. Epub 2018 Nov 5. Clin Chim Acta. 2019. PMID: 30408481
Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNß.
Hurtado-Guerrero I, Pinto-Medel MJ, Urbaneja P, Rodriguez-Bada JL, León A, Guerrero M, Fernández Ó, Leyva L, Oliver-Martos B. Hurtado-Guerrero I, et al. PLoS One. 2017 Jan 19;12(1):e0170031. doi: 10.1371/journal.pone.0170031. eCollection 2017. PLoS One. 2017. PMID: 28103257 Free PMC article.
Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.
Órpez-Zafra T, Pavía J, Hurtado-Guerrero I, Pinto-Medel MJ, Rodriguez Bada JL, Urbaneja P, Suardíaz M, Villar LM, Comabella M, Montalban X, Alvarez-Cermeño JC, Leyva L, Fernández Ó, Oliver-Martos B. Órpez-Zafra T, et al. Among authors: pinto medel mj. Mult Scler. 2017 Jun;23(7):937-945. doi: 10.1177/1352458516667564. Epub 2016 Sep 9. Mult Scler. 2017. PMID: 27613121
18 results